Details

Autor(en) / Beteiligte

• Williams, Lacey S.
• Williams, Kirsten M.
• Gillis, Nancy
• Bolton, Kelly
• Damm, Frederik
• Deuitch, Natalie T.
• Farhadfar, Nosha
• Gergis, Usama
• Keel, Siobán B.
• Michelis, Fotios V.
• Panch, Sandhya R.
• Porter, Christopher C.
• Sucheston-Campbell, Lara
• Tamari, Roni
• Stefanski, Heather E.
• Godley, Lucy A.
• Lai, Catherine

Titel

Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation

Ist Teil von

• Transplantation and cellular therapy, 2024-03, Vol.30 (3), p.255-267

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2024

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •Pathogenic variants in donors and recipients may lead to allo-HSCT complications.•Donor-derived malignancy may arise from donor germline variants or clonal hematopoiesis.•We do not yet have evidence to standardize donor genetic sequencing before allo-HSCT.•Donor variants found after allo-HSCT require ethical disclosure. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a key treatment option for hematologic malignancies (HMs), although it carries significant risks. Up to 30% of patients relapse after allo-HSCT, of which up to 2% to 5% are donor-derived malignancies (DDMs). DDMs can arise from a germline genetic predisposition allele or clonal hematopoiesis (CH) in the donor. Increasingly, genetic testing reveals that patient and donor genetic factors contribute to the development of DDM and other allo-HSCT complications. Deleterious germline variants in CEBPA, DDX41, GATA2, and RUNX1 predispose to inferior allo-HSCT outcomes. DDM has been linked to donor-acquired somatic CH variants in DNMT3A, ASXL1, JAK2, and IDH2, often with additional new variants. We do not yet have evidence to standardize donor genetic sequencing prior to allo-HSCT. The presence of hereditary HM disorders should be considered in patients with myeloid malignancies and their related donors, and screening of unrelated donors should include family and personal history of cytopenia and HMs. Excellent multidisciplinary care is critical to ensure efficient timelines for screening and necessary discussions among medical oncologists, genetic counselors, recipients, and potential donors. After allo-HSCT, HM relapse monitoring with genetic testing effectively results in genetic sequencing of the donor, as the transplanted hematopoietic system is donor-derived, which presents ethical challenges for disclosure to patients and donors. We encourage consideration of the recent National Marrow Donor Program policy that allows donors to opt-in for notification about detection of their genetic variants after allo-HSCT, with appropriate genetic counseling when feasible. We look forward to prospective investigation of the impact of germline and acquired somatic genetic variants on hematopoietic stem cell mobilization/engraftment, graft-versus-host disease, and DDM to facilitate improved outcomes through knowledge of genetic risk. [Display omitted]